FDA approves the first generic naloxone nasal spray to treat opioid overdoses

Cross-posted from Optum Insights blog. On April 19, the U.S. Food and Drug Administration (FDA) approved the first generic for Narcan® Nasal Spray, the life-saving medication used for the emergency treatment of opioid-related overdose. After receiving tentative approval last June, Teva Pharmaceuticals USA Inc. has been granted final approval to market naloxone nasal spray. Teva … Read moreFDA approves the first generic naloxone nasal spray to treat opioid overdoses

FDA requires label changes for opioid analgesics to guide prescribers when gradual tapering is needed

This is a crosspost from the Optum Insights blog. The U.S. Food and Drug Administration (FDA) issued a safety communication in early April that requires changes to prescribing information for opioid analgesics used in outpatient settings. The goal is to expand the information available to health care providers and patients when opioid analgesics have been … Read moreFDA requires label changes for opioid analgesics to guide prescribers when gradual tapering is needed

What you need to know about naloxone

What is naloxone? Naloxone is an opioid antagonist that displaces opioids from receptors in the brain, reversing the effects of opioid analgesics, including their life-threatening effects. Naloxone is commercially available by nasal spray (i.e., Narcan® Nasal Spray), solution for injection and an auto-injector (i.e., Evzio®). Currently, naloxone products are only available by prescription. Naloxone is … Read moreWhat you need to know about naloxone

Changes influencing Medicare Secondary Payer compliance go into effect April 1, 2019

In accordance with the SSN Fraud Prevention Act of 2017, the COB&R program will mask the SSN and SSN-portion of the HICN, on all outgoing letters as of April 1, 2019. The first five digits of the SSN will be masked with asterisks (e.g., *****1234A). All outgoing hardcopy and electronic letters will be included in this … Read moreChanges influencing Medicare Secondary Payer compliance go into effect April 1, 2019